Investment analysts at Barclays PLC initiated coverage on shares of CRISPR Therapeutics AG Common Shares (NASDAQ:CRSP) in a research note issued to investors on Monday. The firm set an “overweight” rating on the stock.

Shares of CRISPR Therapeutics AG Common Shares (NASDAQ:CRSP) opened at 17.50 on Monday. The stock’s market cap is $92.09 million. The company’s 50-day moving average is $15.63 and its 200 day moving average is $15.63. CRISPR Therapeutics AG Common Shares has a 1-year low of $13.75 and a 1-year high of $18.88.

In other news, major shareholder Corp /De/ Celgene purchased 800,150 shares of the business’s stock in a transaction dated Monday, October 24th. The shares were acquired at an average price of $14.00 per share, for a total transaction of $11,202,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Simeon George purchased 66,500 shares of the business’s stock in a transaction dated Monday, October 24th. The shares were purchased at an average price of $14.00 per share, for a total transaction of $931,000.00. The disclosure for this purchase can be found here.

5 Day Chart for NASDAQ:CRSP

Receive News & Stock Ratings for CRISPR Therapeutics AG Common Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics AG Common Shares and related stocks with our FREE daily email newsletter.